---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-22-000049"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:58:04.437500+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere Q3 net loss $69.7M; PDUFA for sparsentan extended to Feb 17, 2023; EMA accepts CMA

## Summary
- Net loss $69.7M ($1.09/share) vs $35.6M ($0.59) YoY; adjusted net loss $48.9M ($0.76).
- Net product sales $50.8M, down from $54.2M; total revenue $53.5M.
- FDA set new PDUFA date Feb 17, 2023 for sparsentan in IgAN after REMS update.
- EMA accepted CMA application for sparsentan in IgAN; decision expected H2 2023.
- Cash, equivalents & marketable securities $506.3M; DUPLEX FSGS data expected H1 2023.

## SEC filing metadata
- accession: 0001438533-22-000049
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/0001438533-22-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/tvtx-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-22-000049
- JSON: https://secwatch.observer/filing/0001438533-22-000049.json
- Plain text: https://secwatch.observer/filing/0001438533-22-000049.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On October 27, 2022, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/0001438533-22-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.